The combination of osimertinib and the MET inhibitor savolitinib showed enhanced efficacy for pre-treated patients with MET-positive, EGFR-mutant NSCLC, regardless of prior treatment with a T790M-directed therapy, with the T790M mutation being frequently detected in brain metastases of lung tumors (the TATTON trial, website: www.ClinicalTrials.gov, identifier: NCT02143466). Here, MET is linked to non-small cell lung carcinoma.